Celltrion Healthcare Co., Ltd. Overview
Celltrion is South Korea's largest biosimilar developer and exporter and one of a small group of vertically integrated global biosimilar players. It develops, manufactures and directly commercialises monoclonal-antibody and recombinant-protein biologics. The December 2023 absorption of Celltrion Healthcare removed a two-tier structure in which the manufacturer sold product to an affiliated distributor. It also brought global direct-sales networks in Europe and the US inside a single P&L. The franchise was built on the first mAb biosimilar, Remsima (infliximab), which still leads European infliximab. Growth is now driven by a "young" portfolio: Remsima SC/Zymfentra, Yuflyma, Vegzelma, Steqeyma, Omlyclo, Stoboclo/Osenvelt, Avtozma and Eydenzelt. These products exceeded 60% of biologics revenue in 2026. FY2025 revenue was KRW 4.16 trillion and operating income KRW 1.17 trillion, both company records. Management is now adding US manufacturing (Branchburg, NJ), CDMO services, French pharmacy distribution (Gifrer) and an early-stage novel-drug pipeline (ADCs, multispecifics, obesity).
What the company does. Celltrion researches, develops, manufactures and sells protein-based therapeutics. The core of the business is biosimilars, which are near-copies of off-patent originator biologics. Products are concentrated in immunology (TNF-α, IL-12/23, IL-6, IgE inhibition), oncology (CD20, HER2, VEGF), bone health (RANKL) and ophthalmology (VEGF-trap). It also has a proprietary new-drug franchise (Zymfentra, a subcutaneous infliximab approved in the US as a new biologic), a chemical-drug and consumer-health arm (via the KOSDAQ-listed subsidiary Celltrion Pharm, ~53.8% owned, and the newly acquired French company Gifrer), and an emerging contract manufacturing (CMO/CDMO) business.
Company's own characterisation (paraphrased). In FY2025 and 2026 disclosures, Celltrion presents itself as a global biopharmaceutical company. It says its strategy combines high-margin new biosimilars, structural cost reduction (titre improvement, depletion of pre-merger high-cost inventory, end of development-cost amortisation) and reinvestment of biosimilar cash flow into follow-on biosimilars and novel drugs (Celltrion Q2 2026 results release, Jul 2026; FY2025 release, Feb 2026). MarketScreener's summary of the business report describes operations as a Bio Pharmaceutical segment producing and selling protein therapeutics, alongside other (chemical/other) activities.
Business and revenue model.
Product sales (dominant): In FY2025, biopharmaceutical product sales were KRW 3,864.0bn, or 92.8% of consolidated revenue of KRW 4,162.5bn (Meritz Securities, Feb 2026; Celltrion FY2025 release).
Non-biologics (chemical drugs, CMO, other): KRW 298.6bn in FY2025 (Meritz, derived). This includes Celltrion Pharm's chemical drugs (e.g., Godex, Dilatrend) and contract-manufacturing revenue.
CMO/CDMO services (rising): A multi-year contract-manufacturing agreement with Eli Lilly began contributing at the Branchburg plant in 2026. Reported value is about USD 473m (American Pharmaceutical Review) or about KRW 678.7bn over three years (Linkareer company summary). Korea Herald reports a four-year contract period. CDMO sales and project management sit in the subsidiary Celltrion BioSolutions, established in 2024 (BioSpectator, Dec 2025).
Licensing / milestone income: Not a material reported line in the sources reviewed.
Subscription: Not applicable.
Value-chain position. After the merger, Celltrion is fully integrated: cell-line development, process development, drug-substance manufacturing (Songdo Plants 1–3; Branchburg, NJ), clinical development, regulatory filings, and direct commercial operations in Europe, North America and other markets. Celltrion Pharm adds domestic distribution and prefilled-syringe (PFS) fill-finish capacity. Gifrer adds French pharmacy distribution.
Customer types.
-
Hospitals and hospital purchasing groups, including national and regional tenders in Europe.
-
US specialty pharmacies, distributors and integrated delivery networks. Access depends on formulary listings with pharmacy benefit managers (PBMs) and insurers; Celltrion reports more than 90% coverage for Zymfentra (Herald Corp, Sep 2026).
-
Government payers (European national health systems; US Medicare/Medicaid indirectly).
-
Retail pharmacies (France via Gifrer; Germany for SC products).
-
Pharmaceutical companies buying CMO services (Eli Lilly).
End-markets served.
-
Autoimmune/inflammatory disease: IBD, rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis.
-
Oncology: NHL/CLL, HER2+ breast and gastric, colorectal, NSCLC.
-
Allergy/immunology: asthma, chronic spontaneous urticaria, food allergy.
-
Osteoporosis and skeletal-related events.
-
Retinal disease: wet AMD, DME, RVO.
-
Hepatology and cardiovascular (chemical drugs, Korea).
-
Consumer health/OTC (France).
Independent characterisation. Celltrion is a scale biosimilar manufacturer-marketer that has moved, within roughly three years, from a captive-distributor model to a direct global commercial organisation. FY2024 profitability was depressed by merger accounting: high-cost inventory bought from the old Celltrion Healthcare and purchase-price-allocation amortisation. The underlying earnings power is now visible in quarterly operating margins of 32–34% in Q2–Q3 2026. Key strategic questions are (a) how fast the young portfolio can grow in the US, where PBM economics and private-label competition limit pricing; (b) whether the novel-drug pipeline produces value beyond biosimilars; and (c) governance and capital allocation in a founder-controlled group.
Strategy
Stated strategic themes (paraphrased from 2025–2026 company materials)
-
Grow the high-margin "young" portfolio to about 70% of biologics revenue. Management expects the new-product share to rise from 54% (FY2025) to around 70% in 2026, which it says will expand the addressable market to more than KRW 400tn (Celltrion FY2025 release; Dealsite).
-
Structural cost reduction. This rests on titre improvement, depletion of pre-merger inventory, the end of legacy development-cost amortisation, and economies of scale. Management describes the margin improvement as structural rather than temporary (Celltrion Q2 2026 preliminary release).
-
US localisation. The Branchburg plant is positioned as the long-term answer to US tariff risk. Celltrion says it has "fully eliminated" potential tariff risk; that is the company's claim (Celltrion shareholder letter, Sep 2025).
-
CDMO as a second growth pillar. Services run through Celltrion BioSolutions. Capacity comes from Branchburg (to 132,000 L) and Songdo Plants 4 and 5 (180,000 L). Recent increases in CMO enquiries are cited as a rationale for new capacity (Asia Economy, Mar 2026).
-
Biosimilar breadth: 30 biosimilars by 2030 and 41 by 2038 (Herald Corp, Jul 2026).
-
Novel drugs: ADCs, multispecific antibodies and obesity. Up to 16 INDs by 2028, with 25 new-drug candidates in development (J.P. Morgan 2026; Herald Corp, Jul 2026).
-
Channel innovation in Europe. Pharmacy distribution in France via Gifrer, with the possibility of extending the model to other European countries (Herald Corp, Aug 2026).
-
AI transformation. 2026 is declared the first year of company-wide AI adoption, including AI-enabled drug discovery to cut development time and cost (Dealsite, Jul 2026).
Strategic initiatives, last 24 months
| Date | Initiative | Detail |
|---|---|---|
| May 2025 | US tariff response plan | Two years of inventory moved to the US; local CMO contracts expanded (BioSpectrum Asia) |
| Sep 2025 | Corporate Value-Up programme | By 2027: average annual sales growth of at least 30%, ROE of at least 7%, three-year average shareholder return of 40%. Medium-term cash dividends to target 30% of (EBITDA − capex) (NewsSpace, Sep 2025) |
| Sep–Dec 2025 | Branchburg acquisition | About KRW 460bn plant price; about KRW 700bn including operating funds; about KRW 700bn more for expansion. Broader plan close to USD 1bn (American Pharmaceutical Review) |
| Nov 2025 | Investment pledge at presidential office | Chairman Seo outlined about KRW 2tn of US investment and KRW 4tn of domestic investment, split into US production and Korean R&D tracks (Metro Seoul, Nov 2025) |
| Jan 2026 | Novel pipeline expansion | Up to 16 INDs by 2028 |
| Mar 2026 | Songdo Plants 4 and 5 | KRW 1.2265tn by 2030; automation and robotics |
| May 2026 | Gifrer acquisition | Management expects more than KRW 250bn of additional revenue over five years (Korea Herald) |
| Jun 2026 | First labour union formed | Social-governance development |
| Jul 2026 | AI Committee | Company-wide AI transformation |
| Sep 2026 | Shareholder return principle | About one-third of annual consolidated net income returned through cancellations or cash dividends (Herald Corp, Sep 2026) |
Medium-term targets and guidance
| Target | Value | Status |
|---|---|---|
| FY2026 revenue | KRW 5.3tn | Management "aims to exceed" (Q2 2026 release) |
| FY2026 operating income | KRW 1.8tn | Same |
| 2026 quarterly operating-income path | KRW 300bn → 400bn → 500bn+ → 600bn | Q1–Q3 exceeded (Herald Corp, Oct 2026) |
| New-product share of biologics revenue | About 70% (2026) | 65% in Q2 2026 |
| Revenue CAGR to 2027 | At least 30% p.a. | Value-Up |
| ROE by 2027 | At least 7% | Value-Up |
| Shareholder return | 40% three-year average (Value-Up); about one-third of net income (Sep 2026 principle) | Ongoing |
| Long-term revenue ambition | KRW 12tn by 2030 (stated at merger, Dec 2023) | Not reiterated in 2026 sources reviewed |
Products & Services
5A. Legacy biosimilar portfolio
Remsima (CT-P13, infliximab IV; reference: Remicade).
Indications: RA, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis.
Approvals: Korea 2012, EU 2013, US 2016 (sold as Inflectra; Pfizer is the US commercial partner per DS Investment research tables).
Performance: IV sales alone exceeded KRW 1 trillion in FY2024 (Dailypharm, Feb 2025). Market share was 59% in Europe and 30% in the US (as Inflectra) in FY2025 (Celltrion FY2025 release). Including Remsima SC, the infliximab franchise held about 68% combined share in Europe in Q3 2025: France 81%, UK 84%, Germany 74% (Linkareer summary of company data).
Recent update: A liquid IV formulation that halves preparation time has been launched (Sat Economy, Feb 2026).
Pricing: Tender and contract pricing; not disclosed.
Truxima (CT-P10, rituximab; reference: Rituxan/MabThera).
Indications: Non-Hodgkin lymphoma, CLL, RA and related conditions.
Approvals: EU Feb 2017; FDA Nov 2018.
Performance: Market share above 30% in both the US and Europe; FY2025 sales up 17.1% YoY (Dealsite, Feb 2026).
Herzuma (CT-P6, trastuzumab; reference: Herceptin).
Indications: HER2+ breast and gastric cancer.
Approvals: EU and US 2018.
Performance: No.1 share in Europe and about 75% share in Japan; FY2025 sales up 10.1% (Dealsite).
Line extension: A subcutaneous trastuzumab completed its pivotal trial. Filings in Europe and Korea were planned within about three months of Feb 2026 (Sat Economy).
5B. New ("young") biosimilar portfolio
Remsima SC (CT-P13 SC, Europe and ex-US).
-
First subcutaneous infliximab; EU approval Nov 2019.
-
About 32% share across the EU5 in Q1 2026. Dose escalation by disease severity is credited with driving share (Herald Corp, Sep 2026).
Zymfentra (infliximab-dyyb SC, US).
-
Approved by the FDA as a new biologic in Oct 2023 for UC and Crohn's maintenance; US launch Mar 2024.
-
Listed on all six public and private plans managed by the three largest US PBMs (KED Global, Oct 2024). Insurer coverage is now above 90% (Herald Corp, Sep 2026).
-
H1 2026 sales were KRW 99.5bn, up 176.4% YoY (Herald Corp, Sep 2026).
-
An IND for a Phase 4 study supporting a 240 mg high-dose regimen was filed in Sep 2026.
Note: Management's 2024 projections (KRW 1tn in 2025, KRW 2tn in 2026) have not been met on the disclosed run-rate.
Yuflyma (CT-P17, high-concentration, citrate-free adalimumab; reference: Humira).
-
EU approval Feb 2021; US approval 2023.
-
Share: 24% in Europe and 5% in the US (Smart Today, Q2 2026 data). The US share later rose to 11% (Newspim summary, Oct 2026).
-
FY2025 sales up 44% YoY (Dealsite).
Vegzelma (CT-P16, bevacizumab; reference: Avastin).
-
Indications: metastatic colorectal cancer, NSCLC and others. EU and US approval 2022.
-
FY2024 global sales were KRW 221.2bn, more than four times the prior year (Dailypharm, Feb 2025).
-
Leads Europe with 26–32% share depending on period (Linkareer; Smart Today); 9% US share (Smart Today).
-
FY2025 sales up 66.8% (Patsnap summary of the FY2025 release).
Steqeyma (CT-P43, ustekinumab; reference: Stelara).
-
Indications: psoriasis, PsA, Crohn's, UC. Approved in the EU and US in 2024; US launch Mar 2025.
-
Two top-five PBM formulary contracts were signed by May 2025, covering about 30% of the US market at that time (NewsSpace, May 2025).
-
US share reached 15% (Newspim summary, Oct 2026).
Omlyclo (CT-P39, omalizumab; reference: Xolair).
-
First omalizumab biosimilar approved in the EU (May 2024), Korea (Jun 2024), Australia (Nov 2024), Canada (Dec 2024; high-dose Jan 2026), US (Mar 2025, with full interchangeability), New Zealand (Apr 2025) and Japan (Mar 2026) (Pearce IP).
-
European rollout began in Norway (Sep 2025) and covered the major markets by Nov 2025; Brazil launch Nov 2025.
-
US commercial launch Sep 2026 (RTTNews). Preferred listing on Optum's formulary supports reimbursement from Q4 2026 (StockHub/Etoday, Oct 2026).
-
Denmark share expected to stay above 98% (Newspim summary).
Stoboclo / Osenvelt (CT-P41, denosumab; reference: Prolia / Xgeva).
-
Approved in the EU and US in early 2025.
-
Celltrion plans to use Gifrer's French pharmacy network as pharmacist substitution expands to denosumab biosimilars (Korea Herald, May 2026).
Avtozma (CT-P47, tocilizumab; reference: Actemra/RoActemra).
-
Approved in the US and EU in early 2025 (World Pharmaceuticals).
-
US availability of the SC formulation announced in 2026 (MarketScreener headline).
Eydenzelt (CT-P42, aflibercept 2 mg; reference: Eylea).
-
Approved in Korea (May 2024), EU (Feb 2025), US (Oct 2025) and Japan (Mar 2026).
-
US launch permitted from 31 Dec 2026 under the Oct 2025 Regeneron settlement (Fierce Pharma; Pearce IP). This is Celltrion's first ophthalmology product.
Combined new launches. Steqeyma, Stoboclo/Osenvelt, Omlyclo, Avtozma and Eydenzelt together exceeded KRW 300bn of FY2025 revenue despite partial-year or pre-launch status in some markets (Celltrion FY2025 release).
5C. Other marketed products
Regkirona (regdanvimab): COVID-19 antibody, approved in Korea and the EU in 2021. Now immaterial.
Chemical drugs (Celltrion Pharm, Korea): - Godex (hepatic agent): KRW 68.4bn in FY2025, +2.4%.
-
Dilatrend (hypertension): KRW 57.4bn, +14.3%.
-
Total chemical-drug sales: KRW 214.0bn (Dealsite, Feb 2026).
-
Celltrion Pharm also distributes Celltrion biosimilars in Korea (KRW 130.6bn in FY2025, +50.8%).
Takeda Asia-Pacific primary-care brands: acquired 2020. A product-level breakdown is not disclosed in the sources reviewed.
5D. Services
CMO/CDMO: At Branchburg, NJ, about half of capacity is earmarked for Eli Lilly products under the CMO contract, with the rest for Celltrion's own products (American Pharmaceutical Review). Celltrion Pharm's PFS contract manufacturing generated about KRW 92.6bn in FY2024 (Dealsite, Mar 2025). CMO revenue also contributed to Q4 2024 revenue (Sidae Ilbo).
5E. Consumer health / OTC (France)
Gifrer: (founded 1912).
-
More than 140 OTC, pharmacy and health-supplement products.
-
No.1 in French saline solutions with a 42% share; 28% share in teeth whitening (Korea Herald, May 2026).
-
Reaches more than 9,000 pharmacies and about 800 hospitals.
-
A dermo-cosmetic product (Zipiderm) is to launch in France in early 2027 (Korea Times, Aug 2026).
5F. Pipeline (development-stage)
| Programme | Modality / reference | Indication(s) | Stage (latest disclosed) |
|---|---|---|---|
| CT-P51 | Pembrolizumab biosimilar (Keytruda) | NSCLC and others | Phase 3. FDA protocol amendment filed Jul 2026; EMA trial application withdrawn Jul 2026 (MarketScreener headlines) |
| CT-P44 | Daratumumab biosimilar (Darzalex) | Multiple myeloma | Phase 3 (Sat Economy, Feb 2026) |
| CT-P52 | Ixekizumab biosimilar (Taltz) | Autoimmune | Phase 1 |
| CT-P45, CT-P68 | Undisclosed biosimilars | Autoimmune | IND filings planned |
| Trastuzumab SC | Herceptin SC biosimilar | Breast cancer | Pivotal trial complete; EU/Korea filings planned 2026 |
| CT-P70 | ADC (biobetter) | NSCLC, colorectal | Phase 1 dosing; FDA Fast Track |
| CT-P71 | ADC (biobetter) | Urothelial, breast, prostate | Phase 1 dosing; FDA Fast Track |
| CT-P73 | ADC | Cervical, head and neck | Phase 1 dosing; Fast Track application planned 2026 |
| CT-P72 / ABP-102 | Tetravalent HER2×CD3 T-cell engager (with Abpro Holdings) | Gastric, breast | Phase 1 dosing; Fast Track application planned 2026 |
| CT-G32 | Quad-agonist peptide (obesity) | Obesity | Preclinical data due Nov 2026; IND targeted by Feb 2027 |
Sources: PR Newswire / Celltrion J.P. Morgan 2026 release; Herald Corp (Jun and Jul 2026); The Investor (Jul 2026). Celltrion says it is developing 25 new-drug candidates in total and plans up to 16 INDs by 2028 (up to 10 ADCs, 4 multispecifics, 1 recombinant protein, 1 peptide). Its biosimilar targets are 30 products by 2030 and 41 by 2038 (Herald Corp, Jul 2026; Sat Economy).
Financial Narrative
Income statement: notes and sources
Sources: Revenue and gross profit from Stockopedia (audited accounts). Operating income, EBITDA, attributable net income and basic EPS from Paasa. Total net income and pre-tax income from Stockopedia. FY2025 company figures (revenue KRW 4,162.5bn, operating income KRW 1,168.5bn, net income KRW 1,031.5bn) from Celltrion's FY2025 release and Dealsite (Feb 2026). Adjusted EPS and DPS from MarketScreener. Diluted EPS is not disclosed in the sources reviewed. The FY2025 nominal DPS was KRW 750 (ex-date 29 Dec 2025, paid Apr 2026; StockEvents).
Margins (%)
Revenue CAGR (derived): FY2021–FY2025: 21.8%. FY2023–FY2025: 38.3%. Both are flattered by the merger-driven change to third-party sales.
Quarterly trajectory, Q1 2025 – Q3 2026
Sources: Meritz quarterly biopharma and non-bio splits (Feb 2026); Celltrion Q2 2026 final results (27 Jul 2026); RTTNews Q3 2026 preliminary (12 Oct 2026); Herald Corp. Q1 2025 operating income is derived from Q1 2026 growth of 115% YoY, and the quarterly sum reconciles to FY2025 operating income of KRW 1,168.5bn. Q3 2026 figures are preliminary.
H1 2026: Revenue KRW 2,538.7bn, operating income KRW 773.7bn, net income KRW 721.2bn, gross margin 61.1% (Q2 gross margin 62.0%) (Quartr summary of Celltrion Q2 2026).
9M 2026 (derived): Revenue about KRW 4,038.7bn; operating income about KRW 1,283.7bn.
Balance sheet
Sources: Stockopedia (audited accounts) for assets, cash, receivables, current items, liabilities and equity. Total debt for FY2023–FY2025 from PitchBook; FY2021–FY2022 from Paasa.
Conflicts: Paasa shows total debt of KRW 1.9tn (FY2023), 2.2tn (FY2024) and 3.7tn (FY2025), well above PitchBook's figures. Definitions likely differ (leases or other financial liabilities). Simply Wall St reported debt of KRW 2.51tn as of June 2025. Wikipedia shows FY2025 equity of KRW 17,352.5bn versus Stockopedia's 17,208.5bn, possibly an attributable-versus-total difference.
Not disclosed in sources reviewed: the short-term/long-term debt split and goodwill and intangibles. The merger created a large equity base, from KRW 4.1tn to KRW 17.0tn, through the share issue to Celltrion Healthcare holders, implying large goodwill and intangible balances. Simply Wall St noted that most liabilities are current: KRW 3.66tn due within 12 months versus KRW 227.1bn beyond, as of mid-2025.
Cash flow
Sources and notes: Paasa (aggregator). Paasa prints FY2022 operating cash flow as "KRW 863.5M," which is assumed to mean KRW bn. Implied capex is derived and should be treated cautiously. The low FY2025 figure probably excludes the Branchburg purchase (about KRW 460bn), which would sit in investing cash flows as an asset acquisition. For FY2024 buybacks, Korea Times cites KRW 436bn, while Eugene Investment states more than KRW 500bn were bought back and cancelled in each of 2024 and 2025. The FY2025 entry is a lower bound. Cash dividends paid are not disclosed in the sources reviewed.
Ratios
All ratios are analyst-derived from the tables above: NOPAT uses effective tax rates implied by pre-tax and net income: about 20.7%, 15.2%, 19.6%, 27.3% and 10.6% for FY2021–FY2025.
Commentary on trends, inflections and drivers
FY2021–FY2023: plateau under the affiliate-sale model. Revenue stayed between KRW 1.9tn and 2.3tn and operating margins were around 28–39%. The pre-merger Celltrion recognised revenue when it sold to Celltrion Healthcare, so reported growth depended on affiliate ordering and inventory build, not end-market demand. FY2022 receivables rose to KRW 1.68tn and aggregator free cash flow turned negative (−KRW 311bn), consistent with inventory and receivable build at the affiliate level.
FY2024: merger accounting depresses profitability. Revenue jumped 63% to KRW 3.56tn as third-party sales were consolidated, but operating income fell 24% to KRW 492.0bn. The operating margin dropped to 13.8% for the year and to single digits in early quarters (Dailypharm). Management attributes this to three factors:
-
High-cost inventory bought from the old Celltrion Healthcare passing through cost of sales.
-
Purchase-price-allocation and development-cost amortisation.
-
A write-off of more than KRW 110bn tied to global rights previously held by Celltrion Healthcare (NewsSpace, Value-Up announcement).
The cost-of-sales ratio was about 63% just after the merger in Q4 2023 and fell to about 45% for FY2024 (BioSpectator).
FY2025: normalisation. Revenue rose 17% to KRW 4.16tn and operating income rose 137.5% to KRW 1.17tn (28.1% margin). Gross margin recovered to about 59%. Q4 2025 alone produced KRW 475.2bn of operating income at a 35.7% margin. The Q4 cost-of-sales ratio was about 36.1%, down from about 39% in Q3 (FN News, Dec 2025). The year still fell short of the original KRW 5.0tn revenue target: management cut the target on 31 Dec 2025, citing patent settlements that delayed launches of several new products (BioSpectator, Dec 2025).
2026 year-to-date: operating leverage. Q1–Q3 2026 revenue grew 36%, 45% and about 46% YoY, and operating margins reached 28%, 32% and 34%. Each quarter beat management's operating-profit targets of KRW 300bn, 400bn and 500bn+ (Herald Corp, Oct 2026). Drivers are new-product mix (65% of biologics revenue in Q2), US direct-sales growth (North American direct sales of KRW 228.7bn in Q2 2026, a first above KRW 200bn; Smart Today), cost improvements, and first CMO revenue from Branchburg.
Balance sheet direction. Leverage remains modest at about 0.9x net debt/EBITDA (FY2025, derived). However, total debt rose about 74% in FY2025 to fund the US plant, tariff-driven US inventory stockpiling and buybacks. Working capital tightened, with the current ratio falling from 2.0x in FY2023 to 1.4x in FY2025. Receivables reached KRW 2.0tn (49% of revenue), a level worth monitoring given European tender payment terms and US channel rebates.
Returns. ROE fell from mid-teens before the merger to 2–6% afterwards. This mainly reflects the roughly KRW 13tn equity increase from the share-for-share merger, not operating deterioration. Management's Value-Up target is ROE of at least 7% by 2027. On the 2026 run-rate (H1 net income KRW 721.2bn), that target looks achievable in 2026 itself.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Biopharmaceuticals revenue (KRW Bn) | 1,971.1 | 3,108.5 | 3,864.0 |
Non-biopharmaceutical revenue (chemical drugs, CMO, other; KRW Bn) | 205.3 | 448.8 | 298.6 |
Total consolidated revenue (KRW Bn) | 2,176.4 | 3,557.3 | 4,162.5 |
Biopharmaceuticals share of revenue (%) | 90.6 | 87.4 | 92.8 |
Biopharmaceuticals YoY growth (%) | — | 57.7 | 24.3 |
Non-biopharmaceutical YoY growth (%) | — | 118.6 | -33.5 |
New portfolio share of biopharma revenue (%) | 26.1 | 38.4 | 54.0 |
New portfolio revenue (KRW Bn, derived) | 514.5 | 1,193.7 | 2,086.6 |
Legacy portfolio revenue (KRW Bn, derived) | 1,456.6 | 1,914.8 | 1,777.4 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 1,893.4 | 2,284.0 | 2,176.4 | 3,557.3 | 4,162.5 |
Revenue growth YoY (%) | 2.4 | 20.6 | -4.7 | 63.4 | 17.0 |
Gross profit (KRW Bn) | 1,087.6 | 1,032.7 | 1,051.9 | 1,681.7 | 2,467.0 |
Operating income (KRW Bn) | 744.2 | 647.2 | 651.5 | 492.0 | 1,168.5 |
EBITDA (KRW Bn; FY2024-25 rounded by source) | 958.3 | 853.0 | 937.8 | 1,100 | 1,500 |
Pre-tax income (KRW Bn) | 738.6 | 626.2 | 671.1 | 576.1 | 1,153.7 |
Net income, total (KRW Bn) | 585.8 | 531.3 | 539.7 | 418.9 | 1,031.5 |
Net income attributable to owners (KRW Bn) | 579.5 | 537.8 | 535.6 | 422.7 | — |
Basic EPS (KRW, unadjusted) | 3,663 | 3,894 | 3,442 | 1,969 | 4,466 |
EPS (KRW, adjusted for bonus issues) | 3,515 | 3,362 | 3,273 | 1,873 | 4,438 |
Dividend per share (KRW, adjusted for bonus issues) | 629 | — | 436 | 687 | 714 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 57.4 | 45.2 | 48.3 | 47.3 | 59.3 |
Operating margin (%) | 39.3 | 28.3 | 29.9 | 13.8 | 28.1 |
EBITDA margin (%) | 50.6 | 37.3 | 43.1 | 30.9 | 36.0 |
Pre-tax margin (%) | 39.0 | 27.4 | 30.8 | 16.2 | 27.7 |
Net margin (%) | 30.9 | 23.3 | 24.8 | 11.8 | 24.8 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026P |
|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 841.9 | 961.5 | 1,029.0 | 1,330.2 | 1,145.0 | 1,393.7 | 1,500.0 |
Operating income (KRW Bn) | 149.8 | 242.5 | 301.4 | 475.2 | 321.9 | 451.8 | 510.0 |
Operating margin (%) | 17.8 | 25.2 | 29.3 | 35.7 | 28.1 | 32.4 | 34.0 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 5,674.1 | 5,891.7 | 19,917.5 | 21,055.2 | 22,334.9 |
Cash and short-term investments (KRW Bn) | 1,206.4 | 573.9 | 731.8 | 1,115.3 | 1,203.8 |
Net receivables (KRW Bn) | 1,164.4 | 1,682.9 | 975.7 | 1,485.4 | 2,033.0 |
Total current assets (KRW Bn) | 3,074.5 | 2,929.8 | 5,009.4 | 5,584.1 | 6,205.3 |
Total current liabilities (KRW Bn) | 1,210.5 | 1,294.1 | 2,470.6 | 3,187.1 | 4,453.8 |
Working capital (KRW Bn) | 1,864.0 | 1,635.7 | 2,538.8 | 2,397.0 | 1,751.5 |
Total debt (KRW Bn) | 744.4 | 792.3 | 1,466.9 | 1,488.6 | 2,589.3 |
Net debt (KRW Bn; negative = net cash) | -462.0 | 218.4 | 735.1 | 373.3 | 1,385.5 |
Total liabilities (KRW Bn) | 1,756.9 | 1,752.3 | 2,936.9 | 3,616.1 | 5,126.4 |
Total equity (KRW Bn) | 3,917.2 | 4,139.4 | 16,980.7 | 17,439.1 | 17,208.5 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | 911.2 | 863.5 | 537.2 | 901.9 | 586.5 |
Free cash flow (KRW Bn, as reported by aggregator) | 589.6 | -311.1 | 183.4 | 568.3 | 478.2 |
Implied capex (KRW Bn, derived = OCF − FCF) | 321.6 | 1,174.6 | 353.8 | 333.6 | 108.3 |
Share buybacks (KRW Bn, approx.) | — | — | — | 436 | 500 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%, net income / average equity) | 16.2 | 13.2 | 5.1 | 2.4 | 6.0 |
ROA (%, net income / average assets) | 11.0 | 9.2 | 4.2 | 2.0 | 4.8 |
ROIC (%, approx.: NOPAT / (equity + net debt), year-end) | 17.1 | 12.6 | 3.0 | 2.0 | 5.6 |
Current ratio (x) | 2.54 | 2.26 | 2.03 | 1.75 | 1.39 |
Total debt / equity (%) | 19.0 | 19.1 | 8.6 | 8.5 | 15.0 |
Net debt / EBITDA (x) | -0.48 | 0.26 | 0.78 | 0.34 | 0.92 |
Asset turnover (x) | 0.35 | 0.39 | 0.17 | 0.17 | 0.19 |
Revenue by Region and Region Margins & Growth (%)
| Metric | FY2023 | FY2024 |
|---|---|---|
Europe biopharmaceutical sales (KRW Bn) | — | 1,546.8 |
North America biopharmaceutical sales (KRW Bn) | 629.3 | 1,045.3 |
Rest of world biopharmaceutical sales (KRW Bn, derived residual) | — | 516.4 |
North America YoY growth (%) | — | 66.1 |
Valuation Snapshot
| Metric | Value | Source / date |
|---|---|---|
Share price | About KRW 180,400–183,600 | NH/Yonhap (close 12 Oct 2026: KRW 180,400); RTTNews (KRW 181,500 on 12 Oct; KRW 183,600 on 3 Jul 2026) |
Market capitalisation | About KRW 41.2tn | Paasa |
1-year return | +7.51% | Paasa |
5-year return | -2.48% | Paasa |
YTD 2026 | +4.19% (Paasa) vs. about -6% (NH, as of 12 Oct 2026) | Conflict between sources; KOSPI pharma index about -27% YTD per NH |
6-month return | -11.09% | Paasa |
Valuation Snapshot by Multiple
| Multiple | Value | Basis / source |
|---|---|---|
P/E (trailing) | 25.9x | Paasa (TTM) |
P/E (FY2025 earnings, derived) | About 40x | KRW 41.2tn ÷ KRW 1,031.5bn |
P/E 2026E / 2027E | 28.7x / 24.9x | MarketScreener (at an earlier, higher price) |
EV/Sales 2026E / 2027E | 8.67x / 7.43x | MarketScreener |
EV/Sales (FY2025, derived) | About 10.3x | EV about KRW 42.6tn (market cap + FY2025 net debt) ÷ FY2025 revenue |
EV/EBITDA (FY2025, derived) | About 28x | EV ÷ FY2025 EBITDA of about KRW 1.5tn |
P/B (FY2025 equity, derived) | About 2.4x | KRW 41.2tn ÷ KRW 17.2tn |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
DPS adjusted for bonus issues (KRW) | 629 | 436 | 687 | 714 |
Dividend yield (%) | 0.38 | 0.25 | 0.40 | 0.41 |
Payout ratio (%, MarketScreener) | 17.9 | 13.3 | 36.7 | 16.1 |
Action by Date
| Date | Action | Size |
|---|---|---|
| 2024 | Buybacks | KRW 436bn (Korea Times) or more than KRW 500bn bought and cancelled (Eugene); sources conflict |
| 2025 | Buybacks and cancellations | More than KRW 500bn (Eugene) |
May 2025 | Bonus issue | 0.04 new shares per share |
Mar–Apr 2026 | Treasury-share cancellation (AGM-approved) | 9.11m shares, about 74% of treasury holdings (Daum). Akros also lists 18.1m shares (KRW 245.4bn) and "KRW 1.71tn" values |
Apr 2026 | Buyback | KRW 100bn (488,977 shares), cancelled Jun 2026 |
May 2026 | Buyback | KRW 100bn (586,927 shares) |
Jun 2026 | Bonus issue | 0.05 new shares per share (about 10.92m shares) |
Sep 2026 | Cancellation | 544,299 shares (about KRW 100bn), effective 30 Sep 2026 |
Cumulative | Three-year cancellations | About 18.6m shares, about 8.4% of issued shares (Alpha Biz / Herald Corp, Jun 2026) |
Analyst Conclusions
Management guidance and consensus
-
FY2026 targets: revenue KRW 5.3tn (+27%) and operating income KRW 1.8tn (+54%). Management says it aims to exceed both (Q2 2026 release).
-
Through 9M 2026 (preliminary Q3), revenue is about KRW 4.04tn and operating income about KRW 1.28tn. The KRW 1.8tn target therefore needs about KRW 516bn of Q4 operating income, against a stated Q4 goal of about KRW 600bn. Management cites European tender deliveries, US PBM listing effects and year-end distributor stocking for Q4.
-
Consensus EPS growth: about +46% in 2026 (MarketScreener: KRW 4,438 → 6,476) and about +13% in 2027.
Bull case
-
Margin structure has reset higher. Gross margin rose from about 47% (FY2024) to 62% (Q2 2026). Quarterly operating margins rose from 18% (Q1 2025) to 34% (Q3 2026). NH expects mid-to-high-30s% in 2027. With R&D fully expensed, this implies significant free cash flow.
-
Launches are lined up. Omlyclo US (Sep 2026, interchangeable, Optum listing from Q4), Eydenzelt US (31 Dec 2026) and full-year effects from denosumab and tocilizumab broaden the base beyond infliximab. New products were already 65% of biologics revenue in Q2 2026.
-
US manufacturing and CDMO add optionality. Branchburg gives tariff protection and immediate Lilly CMO revenue. Plants 4 and 5 add 180,000 L for CDMO demand, a growth leg outside biosimilar pricing.
Bear case
-
US economics may cap upside. Celltrion's US shares in crowded categories (adalimumab 5–11%, bevacizumab 9%) lag Europe sharply. Aflibercept will be one of several biosimilars launching in 2026. PBM private-label arrangements favour competitors.
-
Guidance and capital-allocation credibility. The FY2025 target was cut by about 18% at year-end. Zymfentra fell far short of earlier aspirations. Treasury-share policy was partly reversed (new issuance allowed), and the founder controls the board.
-
Valuation already discounts strong growth. At about 40x FY2025 earnings, about 26x trailing and about 28x 2026E P/E, with ROE near 6% (FY2025), the shares need sustained delivery. Pipeline value (Phase 1 ADCs, preclinical obesity) is speculative.
Key catalysts and monitorables (next 12 months)
-
Q3 2026 final results (expected Nov 2026) and Q4 delivery against the KRW 600bn operating-profit goal and the KRW 1.8tn full-year target.
-
Omlyclo US uptake after Optum reimbursement in Q4 2026; interchangeability-driven substitution.
-
Eydenzelt US launch (31 Dec 2026) and its price and share against six or more aflibercept competitors.
-
Branchburg validation for Celltrion's own products (expected around late 2026 to early 2027) and further CMO contracts.
-
CT-G32 preclinical data (Nov 2026) and IND (target Feb 2027); first ADC Phase 1 data (2027); Fast Track decisions for CT-P72 and CT-P73.
-
CT-P51 (pembrolizumab) Phase 3 redesign and regulatory path.
-
FY2026 dividend and buyback decisions under the one-third-of-net-income principle; any further share-issuance actions.
-
Outcome of the Serious Accidents Punishment Act investigation; labour negotiations with the new union.
-
US trade and tariff measures on pharmaceuticals and Korea-US trade terms.
-
Any revival of a Celltrion Pharm merger or a Celltrion Holdings listing.
Analyst verdict
Celltrion in late 2026 has emerged from the accounting turbulence of its December 2023 absorption of Celltrion Healthcare. It is now operating as a single, vertically integrated biosimilar company with materially better economics. The numbers support this. FY2025 operating income more than doubled to KRW 1.17tn, and Q3 2026 preliminary operating income of KRW 510bn on KRW 1.5tn revenue implies a 34% margin, up from high-teens percentages in early 2025. This improvement is mostly mechanical and durable: pre-merger high-cost inventory has run off, legacy amortisation has ended, titres have improved, and new products are a higher share of sales. It does not depend on optimistic market assumptions.
The investment debate has therefore shifted from "will margins recover?" to "how far can the US scale, and what is the pipeline worth?" In Europe, Celltrion is a category leader with proven tender and direct-sales capabilities. In the US, it is still a mid-tier player in several crowded molecules. The 2026–2027 launch slate (Omlyclo with interchangeability, Eydenzelt, Steqeyma's growth) and Branchburg's tariff hedge are the right tools, but execution through PBMs remains the main swing factor. CDMO and the French pharmacy model are sensible diversifications, though too small to move the group materially before 2027–2028.
Balance-sheet risk is limited (net debt about 0.9x EBITDA), but working capital and short-dated liabilities deserve watching. Governance is the persistent discount factor. The founder and his son jointly chair the board, policy on treasury shares has shifted, and Sustainalytics rates ESG risk management weak. Shareholder returns have become more systematic, with a target of about one-third of net income.
On balance, Celltrion offers credible near-term earnings momentum and improving cash returns. The valuation already assumes delivery of the 2026–2027 plan. The most informative data points will be Q4 2026 delivery, US uptake of Omlyclo and Eydenzelt, and the first clinical readouts from the novel pipeline.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / appointment | Prior roles and background | Age / birth year |
|---|---|---|---|---|
Seo Jung-jin | Chairman, Celltrion Group; inside director; joint chairperson of the board | Founder (2002). Left board Mar 2021; returned Mar 2023 | Formerly Samsung Electro-Mechanics and Daewoo Motor; founded Nexol and Celltrion | Born 1957 (public record) |
Seo Jin-seok | CEO; inside director; joint chairperson of the board | Board since Mar 2021; co-CEO since Dec 2023 merger | Former head of Product Development Unit; former CEO of Celltrion Skincure | — |
Kee Woo-sung | CEO / Vice Chairman (Manufacturing & Development); inside director | Director since 2007 (MarketScreener) | Former VP, Nexol Biotech; Daewoo Motor planning office | Born 1961 (Yahoo) |
Kim Hyoung-ki | CEO / Vice Chairman (Global Sales); inside director | Co-CEO since merger; former CEO of Celltrion Healthcare | Former director, Nexol Biotech; Daewoo Motor strategic planning | Born 1965 (Yahoo) |
Seo Jung-su | Vice Chairman | Since 2024 | Former CEO, Celltrion Pharm | — |
Choi Byeong-seo | President (Executive Committee) | Listed Feb 2026 | — | — |
Lee Hyuk-jae | Senior EVP, head of Product Development | — | Co-presented pipeline at J.P. Morgan 2026 | — |
Shin Min-cheol | Head of Management Division / finance | — | — | Born 1971 (Yahoo) |
Choi Ji-hoon | Head of Legal Affairs | — | — | Born 1971 (Yahoo) |
Independent directors (per company governance page) | Includes a lawyer (Lee Joong Jae Law Firm; ex-Kim & Chang); a CPA (partner, BDO Korea; ex-Samil PwC); and an honorary rheumatology professor (Hanyang University College of Medicine; former president, Korean College of Rheumatology). MarketScreener also lists Lee Soon-woo as a director. | Several previously sat on the Celltrion Healthcare board | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change |
|---|---|
Mar 2021 | Founder retires; son becomes board chair |
Mar 2023 | Founder returns as chairman of the holding company and all three listed affiliates |
Dec 2023 | Three-CEO structure adopted at the merger |
| 2024 | Seo Jung-su (ex-Celltrion Pharm CEO) becomes Vice Chairman |
Feb 2026 | Choi Byeong-seo listed as President |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Celltrion Holdings Co., Ltd. | 20.05% | Wikipedia |
Celltrion Skincure | 2.11% | Wikipedia |
Seo Jung-jin (via about 98% ownership of Celltrion Holdings) | Indirect control | JoongAng Daily; Yonhap |
Free float | About 60.6% | MarketScreener |
Retail investors | About 67% of Celltrion shareholders (2023) | JoongAng Daily, Mar 2023 |
Competitive Landscape
Competitors by Segment
| Segment | Key competitors (named) |
|---|---|
Infliximab / TNF | Originator J&J (Remicade); Pfizer (Inflectra is Celltrion-made); Sandoz; Samsung Bioepis/Organon; Amgen; Biocon Biologics |
Adalimumab | AbbVie (Humira); Sandoz (Hyrimoz, incl. private label); Amgen; Samsung Bioepis/Organon; Alvotech/Teva; Fresenius Kabi; Biocon |
Ustekinumab | J&J (Stelara); Sandoz (Pyzchiva, with Samsung Bioepis); Amgen; Alvotech/Teva; Biocon; Fresenius Kabi |
Omalizumab | Novartis/Genentech (Xolair). |
Denosumab | Amgen (Prolia/Xgeva); Sandoz; Samsung Bioepis; Fresenius Kabi; Biocon; Alvotech (AVT03); Chinese developers |
Aflibercept | Regeneron/Bayer (Eylea); Amgen (Pavblu, launched Oct 2024); Sandoz (Enzeevu); Biocon/Mylan (Yesafili); Samsung Bioepis (Opuviz); Formycon (Ahzantive); Alvotech (AVT06) |
Rituximab / trastuzumab / bevacizumab | Roche/Genentech originators; Pfizer; Amgen; Sandoz; Samsung Bioepis; Biocon; Henlius |
Tocilizumab | Roche/Chugai (Actemra); Biogen/Bio-Thera; Fresenius Kabi |
CDMO | Samsung Biologics; Lonza; WuXi Biologics; Fujifilm Diosynth |
Peer Comparison FY2025
| Company | Latest FY | Revenue | Growth YoY (%) | Operating / EBITDA margin (%) | R&D intensity (%) |
|---|---|---|---|---|---|
Celltrion | FY2025 | KRW 4,162.5bn (about USD 2.84bn) | 17.0 | 28.1 (operating) | 11.6 |
Sandoz | FY2025 | USD 11.1bn (biosimilars about 30%) | 5 (cc); 7 (USD); biosimilars +13 (cc) | — | — |
Samsung Bioepis | FY2025 | KRW 1,672bn (product sales KRW 1,626bn) | 9 (total); 28 (product sales) | 22.5 (operating, total) | — |
Alvotech | FY2025 | USD 593m | 21 | 23.1 (adjusted EBITDA) | — |
“—” = not publicly disclosed.



